Samir et al. [84] reported that treating type 2 diabetes mellitus (T2DM) with L-carnitine resulted in improved immunohistochemical intensity of TRIM63. We also observed that the immunohistochemical staining intensity of markers that exacerbate skeletal muscle atrophy in T1DM, such as FBXO32, TRIM63, and FoxO3a, decreased in response to treatments. The gene discussed is FOXO3; the disease is type 2 diabetes mellitus.